




AultCare Rx Insights

AultCare understands the significant importance of pharmacy spend and how now, more than ever, employers are taking a closer look at the cost and complexity of numerous medications. Our pharmacy team continuously studies the market, identifying strategies to control pharmacy spend for our clients and members. This newsletter serves as a resource to learn about the latest pharmacy information and trends. Our intent is to provide insightful information to help you optimize your pharmacy benefits.

To view the OptumRx® RxOutlook® for the 4th quarter of 2020, please [click here](#).

Pipeline Products:

Pipeline Forecast



Notable Products:

Drug	Manufacturer	Indication	Route	Specialty	Orphan	Forecast Cost	Est. Release Date
Evinacumab	Regeneron	Homozygous Familial Hypercholesterolemia (HoFH)	IV	Yes	Yes	\$450,000 per year	2/2021
Tanezumab	Pfizer/Lilly	Osteoarthritis Pain	SC	Yes	No	\$11,000 per year	4-6/2021
Aducanumab	Biogen	Alzheimer's Disease	IV	Yes	No	\$50,000 per year	3/2021

Upcoming Generics:

Brand Name	Generic Name	Brand Manufacturer	Dosage Form	Strengths Available as Generic	Possible Launch Date
Northera	deoxidopa	H. Lundbeck	Capsule	All	Feb-21
Myalept	metreleptin	Aegerion	Subcutaneous	All	Feb-21
Fortical	calcitonin salmon recombinant	Upsher-Smith	Intranasal	All	Feb-21
Impavido	Miltefosine	Knight Therapeutics	Capsule	All	Mar-21
Actoplus Met XR	pioglitazone/metformin	Takeda	Tablet, extended release	All	Mar-21
Neupro	rotigotine	UCB	Transdermal Patch	All	Mar-21
Pomalyst	pomalidomide	Celgene	Capsule	All	2Q-2021
Lyrica XR	pregabalin	Pfizer	Tablet, extended release	All	Apr-21
Eraxis	anidulafungin	Pfizer	IV	All	Apr-21
Zomig	zolmitriptan	Impax/Grunenthal	Intranasal	All	May-21
Perforomist	formoterol fumarate	Mylan	Inhalation	All	Jun-21
Intelence	etravirine	Janssen	Tablet	All	Jun-21


Biosimilar Market Expansion:

Biologic products are a diverse category of products used to diagnose, prevent, treat, and cure diseases/medical conditions. Biologic products consist of large complex molecules that are challenging and expensive to manufacture. These products have a big impact on pharmacy/medical spend because from the less than 2% of Americans that use biologics, they account for almost 40% of all prescription spending in the US.


Biosimilar products are lower-cost biologic alternatives to the original FDA-approved reference products. However, unlike traditional generic drugs these large molecule drugs are complex and variations that occur in the manufacturer process prevents these products from being substituted like traditional small molecule generic drugs. The FDA approval process for biosimilar products is designed to ensure that they have demonstrated that they are highly similar to and have no clinically meaningful differences to the reference product. However, because these products are not substitutable like traditional small molecule generic drugs it is important to encourage the use of these biosimilar products.

Biosimilar products in the US are estimated to cost 15%-35% less than the reference products but have no significant clinical differences. As biosimilar products continue to expand in the market place it is important for health plans to put strategies in place to encourage biosimilar use whenever possible. This can be accomplished through the use of Step edits during the Prior Authorization process. AultCare continues to encourage the use of biosimilar products as these useful products expand in the marketplace.

Biosimilar Market Share



Treatment Cost - Allowed Amt



Emerging Therapies:

- CAR-T therapy being reviewed for first line therapy for high-risk large B-Cell lymphoma and use in Multiple Myeloma.
- Diabetes Cell Therapy: The FDA has been cleared VX-880 new drug application for allogenic stem-cell derived pancreatic islet cell therapy. The goal of this therapy is to restore islet cell function in individuals with Diabetes Type I and reestablish the patient's ability to regulate glucose levels.